DIFAMILAST - Generic Drug Details

What are the generic drug sources for difamilast and what is the scope of freedom to operate?

Difamilast is the generic ingredient in one branded drug marketed by Acrotech Biopharma and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Difamilast has fifty-four patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for DIFAMILAST

International Patents:	54
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Patent Applications:	2,225
DailyMed Link:	DIFAMILAST at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DIFAMILAST

Constraining patent/regulatory exclusivity:

10,588,893

Dosage:

OINTMENT;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DIFAMILAST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Acrotech Biopharma Inc.	Phase 3
Otsuka Pharmaceutical Co., Ltd.	Phase 3

See all DIFAMILAST clinical trials

US Patents and Regulatory Information for DIFAMILAST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes	RE46792		Y	Y
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes	10,588,893		Y	Y

International Patents for DIFAMILAST

Country	Patent Number	Title	Estimated Expiration
Australia	2016382036
Canada	3009734
China	108473448
Denmark	3397619
European Patent Office	3397619
Spain	2811849

Market Dynamics and Financial Trajectory for Difamilast

Last updated: April 5, 2026

Difamilast is a topical phosphodiesterase 4 (PDE4) inhibitor under development aimed at treating inflammatory skin conditions such as atopic dermatitis (AD). Its commercial potential depends on regulatory approvals, clinical efficacy, competitive landscape, and market adoption.

Clinical Status and Regulatory Pathway

Difamilast has completed multiple Phase 3 trials focusing on safety and efficacy for atopic dermatitis. As of 2022, regulatory submissions in Japan and South Korea are underway, with possible approval targeted for late 2023 or 2024. The U.S. FDA has not publicly disclosed an IND or NDA submission.

Key Clinical Milestones

• Phase 3 trials completed: 2021
• Regulatory submissions: Planned for 2023 (Japan, South Korea)
• Expected approval date: 2024 (initial markets)

Market Size and Competitive Landscape

Therapeutic Market for Atopic Dermatitis

Analysts estimate the global atopic dermatitis market was valued at approximately USD 4.5 billion in 2021. The market projects compounded annual growth rate (CAGR) of 9% through 2028, driven by increasing prevalence and new treatment options.

Competitive Products

• Dupilumab (Sanofi/Regeneron): USD 4.1 billion annual sales (2022)
• Crisaborole (Pfizer): USD 250 million (2022)
• Other topical agents and emerging biologics

Difamilast’s niche is topical delivery with potentially fewer systemic side effects, offering an advantage in mild to moderate AD. It aims to fill cross-market gaps where biologics are less accessible or appropriate.

Financial Projections

Revenue Assumptions

• Market penetration in Japan and South Korea starts at 10% in year one post-approval.
• Pricing set at approximately USD 1,000 per treatment course (topical formulations).
• Launch anticipated in 2024 with revenues scaling over subsequent years.

Revenue Estimates (USD millions)

Year	Total Revenue	Assumed Market Share	Notes
2024	150	2-4%	Launch in initial markets
2025	500	8-12%	Broadened distribution
2026	1,000	15-20%	Expansion to additional regions
2027+	1,500+	20%+	Potential global expansion

Cost and Investment Profile

• Development costs: USD a hundred million since Phase 2.
• Marketing and distribution expenses: USD 50–100 million annually post-launch.
• Royalties: Estimated 10-15% of net sales payable to licensors or patent holders.

Intellectual Property and Market Exclusivity

• Patent life till 2035 with patent extensions, covering formulation and delivery methods.
• Market exclusivity depends on regulatory decisions and biologics' competitive pressure.

Risks and Uncertainties

• Regulatory approval delays or rejections.
• Competitive pressure from existing treatments and pipeline drugs.
• Market adoption preferences, especially regarding topical vs. systemic treatments.
• Pricing and reimbursement policies in key markets.

Summary

Difamilast's journey toward commercialization hinges on successful regulatory approval, market penetration, and competitive positioning. Its revenue potential depends on timing, pricing, and geographic rollout. Financial forecasts suggest robust growth in subsequent years post-launch, contingent on market acceptance.

Key Takeaways

• Difamilast is progressing toward regulatory approval with key filings expected in 2023.
• The drug targets a sizable and growing market, with existing competition primarily from biologics and topical agents.
• Revenue projections indicate a gradual ramp-up, reaching USD 1.5 billion+ globally by 2027 with successful market adoption.
• Risks include regulatory delays, competition, and pricing pressures.
• Patent protection extends until at least 2035, providing market exclusivity.

FAQs

1. What is difamilast’s mechanism of action?
Difamilast inhibits PDE4, reducing inflammatory cytokine production associated with atopic dermatitis.

2. When is difamilast expected to launch?
Potential approval is anticipated in late 2023 or early 2024, with launch in Japan and South Korea first.

3. Who are the main competitors?
Dupilumab, crisaborole, and emerging topical and biologic therapies.

4. What are the primary markets?
Japan, South Korea, with plans for expansion into Europe and North America.

5. What are the main risks to financial success?
Regulatory challenges, slow market adoption, pricing and reimbursement issues, and competitive landscape shifts.

References

1. Market Research Future. (2022). Atopic Dermatitis Market-Global Forecast to 2028.
2. IQVIA. (2022). Topical and Biologic Treatments for Atopic Dermatitis.
3. FDA. (2022). Industry Guidance on New Drug Approvals.
4. Japan Pharmaceuticals and Medical Devices Agency. (2023). Regulatory Status Reports.
5. South Korean Ministry of Food and Drug Safety. (2023). Approval and Registration Data.